Tuesday morning, right before the S&P 500 (SPX) ripped 2% in a straight line into today, I offered a quick take on the technical set up of the index using a few time-frames (MorningWord 5/24/16: Fool Me Twice? – …
Continue readingBMY
Last night on CNBC’s Fast Money Meg Tirrell interviewed Merck CEO Ken Frazier. As usual, Meg ran a great interview. Since healthcare related stocks are not my forte I found myself looking down at my Bloomberg …
Continue reading
We have been watching ABBV with frustration over the past month, as the stock has flirted with breaking out to a new all-time high on many occasions, but has failed each time: The inability of …
Continue reading
We originally put on our ABBV position at the start of January, as we liked both the fundamental and technical outlook for the stock. Since then, ABBV has had a rocky ride, making a new …
Continue reading
ABBV was one of our first additions to our investment portfolio in 2014 (details below). We had some success on the long side in the fall after detailing the positive pipeline results and the relatively …
Continue reading
Here’s the next addition to our investment portfolio:
Continue reading
Single stock options, particularly in large cap tech, dominated much of the large blocks today as investors look to be adjusting positions into year end with a good amount of rolls dominating the action. 1. …
Continue reading
Abbvie has made several attempts in the past month to break above the $50 level, which it first touched in late October. The company had good Hepatitis C Treatment data in Phase III results released …
Continue reading
Abbott was one of the largest pharmaceutical companies in the world prior to its split in December 2012. The company spun off its proprietary pharmaceutical business (classic business of developing drugs for FDA approval and …
Continue reading